Pneumatica Bio is an Australian biotechnology start-up that predicts the therapeutic activity of novel drugs using preclinical experiments
We unite biology, engineering, and computation to transform how next-generation therapeutics are designed and developed. Our predictive platform accelerates discovery, reduces risk, and helps ensure that breakthrough therapies reach patients faster.
THE
FUTURE
IS
PREDICTIVE
The Problem
The pathway for new therapeutics is long and treacherous.
It takes more than a decade and billions of dollars for a drug to reach the market. Despite this, 90% of drugs that make it as far as clinical trials still fail. Each failure represents not just wasted resources, but tragic stories of the consequences suffered by the patients who remain without a viable treatment.
*Stochastic simulation model derived from Di Masi et al., “Innovation in the pharmaceutical industry: new estimates of R&D costs,” Journal of Health Economics.
The Opportunity
A new generation of therapeutic modalities is reshaping medicine.
Exciting technologies, like mRNA-encapsulating lipid nanoparticles, are rewriting the rules, enabling complex payloads to be delivered directly to target cells with minimal toxic side effects.
But the clinical pathway is still broken. Hundreds of billions are wasted each year on pharmaceutical R&D for failed candidates. Therapeutic design is too dependent on trial and error – wasting time, capital, and opportunity.
Next-generation therapeutics are fundamentally different. Our understanding of their unique behaviour – built on decades of research experience – means we can build a new predictive pathway that avoids the pitfalls of clinical translation, and brings therapies to patients faster.
Therapeutics are undergoing a revolution. Translation deserves one as well.
Our Vision
At Pneumatica Bio, we want to build a predictive future.
A future with personalised medicine. A future with cures to rare diseases. A future where clinical trial failures are a relic of history.
This future requires everyone. By uniting fields and perspectives, Pneumatica Bio moves with more speed, intelligence and precision.
We help realise the potential of next-generation therapeutics, and turn preclinical promise into real impact for patients. Our efficient and high-throughput platform mitigates financial risks in clinical trials and streamlines drug development pipelines.
We have partnered with Australian and overseas companies to provide therapeutic predictions. If you are developing a transformative therapy, and want to understand how it will perform in the body before spending millions on trials, let’s chat!
Our Approach
Our predictive pipeline is built on four key pillars:
Robotics and
Automation
Biology is the bottleneck, not drug discovery.
Our automated experimental platform means we can scale up data generation to ensure our predictive inputs stay cost-effective while remaining rich in biological information.
Next-Gen
Therapeutics
The next generation of therapies requires a next-generation playbook.
Our techniques are tailored to the unique behaviour and interactions of exciting novel therapeutics like nanoparticles and biologics.
Accountable
Intelligence
Decision making in drug development needs to be transparent.
Our predictive pipeline blends mechanistic computational models with AI/ML for interpretable predictions consistent with our knowledge of physics and biology.
Therapeutic
Insight
Drugs do not work unless they reach the target site.
Our proprietary quantitative insights allow us to predict therapeutic distribution and response throughout the body.
If you want to know more details about our approach, reach out for a chat!
About
Pneumatica Bio is a Melbourne-based biotechnology start-up pioneering clinical prediction of novel therapeutics.
The future of medicine is dynamic and increasingly multidisciplinary. Our Founders bring together expertise in biological automation, software development, biomedical engineering, computational modelling, and AI/ML.
Our Founders have worked for world-leading companies and helped scale technology startups. We have published groundbreaking scientific research on next-generation therapeutics and AI/ML, including the first quantitative approaches for evaluating performance. With backgrounds spanning academia and industry, we are uniquely positioned to turn innovation into impact.
See more about our Team here. We are located here.